Analytical Data
-
Gene name
ME20M
- Application
-
Alternative Names
PMEL; GP100; SI; SIL; SILV; Pmel17; Silver Homolog; Premelanosome Protein; Silver Locus Protein Homolog; 95 kDa melanocyte-specific secreted glycoprotein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P40967
-
Expression Region
Gln470~Val661
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ME20M is a recombinant protein that has garnered attention due to its potential applications in various fields, particularly in immunology and biotechnology. Originally derived from the human immune system, ME20M is recognized for its ability to bind specifically to certain cancer cell types, making it a promising candidate for targeted cancer therapies. Research into ME20M began as scientists sought to explore novel approaches to enhance the specificity and efficacy of immunotherapy. The advent of recombinant DNA technology has enabled the production of ME20M in more abundant and consistent quantities, facilitating extensive studies on its mechanism of action and biological functions. Investigations have revealed that ME20M may play a crucial role in modulating immune responses, potentially overcoming challenges associated with traditional cancer treatments. Furthermore, ongoing studies aim to characterize its interactions with cellular receptors and its effects on tumor microenvironments. The exploration of ME20M is not only pivotal for developing next-generation therapeutic agents but also for advancing our understanding of immune system dynamics and their implications in cancer biology. As such, ME20M stands at the intersection of molecular biology and clinical application, representing a significant step forward in the quest for more effective cancer treatments.
